NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/11/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization836.14 mln
Float64.96 mln
Earnings Date05/12/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.21
Manipulation likely
1-Year Forecast
31.17
Transformational upside
Relative Strength
76
/ 100
Strongly outperforming
Debt / Equity
0.12
Very low leverage
ROE
-92.88
Deeply negative
Business Description
Kura Oncology is a San Diego-based pharmaceutical company focused on developing new treatments for cancer and other serious diseases. Its first approved drug, KOMZIFTI, targets a specific protein involved in cancer growth and is taken by mouth. The company is also running early-stage trials for darlifarnib, testing it alongside other treatments for patients with solid tumors, while advancing a newer compound called KO-7246 aimed at diabetes and heart-related conditions.
